Edward Bamus Masoambeta

Mr. Edward Bamus Masoambeta

Health Economics, Kamuzu University of Health Sciences, Lilongwe, Malawi
orcid
Researcher

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2025 in Health Economics Review
Verified
Journal Article
Open access
PDF file
Edward Bamus MasoambetaEdward Bamus Masoambeta
Edward Bamus Masoambeta
CMCharity Mkwanda
Charity Mkwanda
EIEdna Ibrahim
Edna Ibrahim
KCKenneth Chizani
Kenneth Chizani
CCChikondi Chapuma
Chikondi Chapuma
JCJobiba Chinkhumba
Jobiba Chinkhumba
This review examined methodologies used to cost the impact of antimicrobial resistance (AMR) infections in humans from household and health system perspectives. Although extensive research has been conducted on the clinical AMR burden in low- and middle-income countries (LMICs) in terms of prevalence and other drivers of antimicrobial resistance, there is increased misuse and overuse of antibiotics which increases the risk of AMR infections compared to high-income countries. Lack of comprehensive estimates on economic costs of AMR in LMICs due to lack of standard methodologies that incorporate time biases and inference for instance, may negatively affect accuracy and robustness of results needed for reliable and actionable policies. We conducted a systematic review of studies searched in PubMed and other electronic databases. Only studies from LMICs were included. Data were extracted via a modified Covidence template and a Joanna Briggs Institute (JBI) assessment tool for economic evaluations to assess the quality of the papers. Using PRISMA, 2542 papers were screened at the title and abstract levels, of which 148 were retrieved for full-text review. Of these, 62 articles met the inclusion criteria. The articles had a quality assessment score averaging 85%, ranging from 63 to 100%. Most studies, 13, were from China (21%), followed by 8 from South Africa (13%). Tuberculosis (TB), general bacterial, and nosocomial infection costs are the most studied, accounting for 40%, 39%, and 6%, respectively with TB common in South Africa than the rest of the countries. The majority of the papers used a microcosting approach (71%), followed by gross costing (27%), while the remainder used both. Most studies analyzed costs descriptively (61%), followed by studies using regression-based techniques (17%) and propensity score matching (5%), among others. Overall, the use of descriptive statistics without justification, limited consideration for potential data challenges, including confounders, and short-term horizons suggest that the full AMR cost burden in humans in LMICs has not been well accounted for. Given the limited data available for these studies, the use of a combination of methodologies may help triangulate more accurate and policy-relevant estimates. While the resources to conduct such cost studies are limited, the use of modeling costs via regression techniques while adjusting for cofounding could help maximize robustness and better estimate the vast and varied burden derived directly and indirectly from AMR.

30 May 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
EIEdna Ibrahim
Edna Ibrahim
CMCharity Mkwanda
Charity Mkwanda
Edward Bamus MasoambetaEdward Bamus Masoambeta
Edward Bamus Masoambeta
LSLuigia Scudeller
Luigia Scudeller
TKTomislav Kostyanev
Tomislav Kostyanev
CMChisomo Lawrence Msefula
Chisomo Lawrence Msefula
Background/Objectives: Wastewater treatment plants (WWTPs) serve as a sink for both antimicrobial residues and bacteria carrying resistant genes, which are later disseminated into the environment, facilitating the spread of antimicrobial resistance. This study investigated the presence of extended-spectrum beta-lactamase (ESBL) producing Escherichia coli (Ec), Klebsiella pneumoniae (Kp), and Enterobacter cloacae (Enc) in effluent from WWTP in Blantyre, Malawi, to generate evidence and provide baseline information for interventions. Methods: Selective chromogenic agar was used to identify ESBL-producing bacteria. Results: A total of 288 samples were collected between April 2023 and March 2024, and 97.6% (281/288) yielded one or more presumptive ESBL isolates. Bacterial growth was confirmed as 48.9% Ec (255/522), 33.0% Kp (172/522), and 10.0% Enc (52/522). Antibiotic susceptibility testing showed the highest resistance to ceftriaxone (Ec, 100.0%; Kp, 98.3%; Enc, 100.0%) and the lowest resistance to meropenem (Ec, 6.3%, Kp, 1.2%; Enc, 3.8%) among the antibiotics that were tested. Multiple antibiotic resistance phenotypes were observed in 73.1% of the isolates, with the most prevalent phenotype being amoxicillin + clavulanate/cotrimoxazole/doxycycline/ciprofloxacin/gentamicin/azithromycin/ceftriaxone (55, 15.7%). Conclusions: The study demonstrated ongoing environmental contamination with antibiotic-resistant bacteria from sewage effluent. Therefore, the functionality of WWTPs should be improved to minimize the release of these organisms into the environment.

26 March 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
EIEdna Ibrahim
Edna Ibrahim
CMCharity Trinity Mkwanda
Charity Trinity Mkwanda
Edward Bamus MasoambetaEdward Bamus Masoambeta
Edward Bamus Masoambeta
LSLuigia Scudeller
Luigia Scudeller
TKTomislav Kostyanev
Tomislav Kostyanev
CMChisomo Lawrence Msefula
Chisomo Lawrence Msefula
Background/Objectives: Wastewater treatment plants (WWTP) serve as a sink for both antimicrobial residues and bacteria carrying resistant genes which are later disseminated into the environment, facilitating the spread of antimicrobial resistance. This study investigated the presence of extended spectrum beta-lactamase (ESBL) producing Escherichia coli (Ec), Klebsiella pneumoniae (Kp) and Enterobacter cloacae (Enc) in effluent from WWTP in Blantyre, Malawi, to generate evidence and provide baseline information for interventions. Methods: Selective chromogenic agar was used to identify ESBL-producing bacteria. Results: A total of 288 samples were collected between April, 2023 and March, 2024 and 97.6% (281/288) yielded one or more presumptive ESBL isolates. Bacterial growth was confirmed as 48.9% Ec (255/522), 33.0% Kp (172/522) and 10.0% Enc (52/522). Antibiotic susceptibility testing showed higher resistance to ceftriaxone (Ec, 100.0%; Kp, 98.3%; Enc, 100.0%) and lower resistance to meropenem (Ec, 6.3%, Kp, 1.2%; Enc, 3.8%) among the antibiotics that were tested. Multiple antibiotic resistance phenotypes were observed in 73.1% of the isolates with the most prevalent phenotype as AUG-SXT-DXT-CIP-GM-ATH-CRO (55, 15.7%). Conclusions: The study demonstrated ongoing environmental contamination with antibiotic resistant bacteria from sewage effluent. Therefore, the functionality of WWTP should be improved to minimize the release of these organisms into the environment.

6 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Edward Bamus MasoambetaEdward Bamus Masoambeta
Edward Bamus Masoambeta
GNGanizani Nansongole
Ganizani Nansongole
LSLuigia Scudeller
Luigia Scudeller
TKTomislav Kostyanev
Tomislav Kostyanev
FLFinola Leonard
Finola Leonard
CMChantal M Morel
Chantal M Morel
Background: Antimicrobial resistance (AMR) poses a significant threat to global health and economic development. In Malawi, the economic costs associated with AMR remain largely unknown which may hinder resource allocation and policy prioritization. Method: The study used instrumental variable 2-stage least squares regression to analyze patient level cost data at tertiary and secondary level facilities primarily collected from 610 patients with urinary tract infection (UTI) or blood stream infection (BSI) using a questionnaire. Results: Findings indicate that E. coli (43%) followed by K. pneumoniae (14%), and S. aureus (10%) were common pathogens overall. UTI was common (51%) compared to BSI (49%) yet BSI had a higher average cost than UTI for both susceptible and resistant patient categories. In terms of costs, a patient spent MK283,815.10 (US$163.71) on average as a result of AMR infection. The total cost reached as high as MK13,500,000 (US$7,786.90). Patients with a resistant infection incurred, on average MK161,785 (US$93.32) more than patients whose infection was susceptible, with the additional costs being driven by prolonged hospitalization among other factors. The direct medical costs averaged MK37,165.29 (US$21.44) while direct non-medical costs averaged MK61,908.71 (US$35.71). Productivity losses for the patient and guardian(s) were a major cost averaging MK160,322.80 (US$92.49). The regression results further showed that having a bank account as a proxy of wealth, non-farm business, longer travel duration, BSI, and K. pneumoniae as causing pathogens were significantly associated with increased cost burden among the patients. Conclusions: AMR imposes substantial economic burden on Malawi's health system, with most costs falling on patients. Further strengthening of AMR surveillance and stewardship are needed as critical elements of Malawi’s National Action Plan. However, measures should also be taken to mitigate the economic consequences related to AMR, especially for patients who bear the brunt of these costs for lack of financial protection in Malawi’s health system.

Verified
Journal Article
Open access
PDF file
Edward Bamus MasoambetaEdward Bamus Masoambeta
Edward Bamus Masoambeta
GNGanizani Nansongole
Ganizani Nansongole
LSLuigia Scudeller
Luigia Scudeller
TKTomislav Kostyanev
Tomislav Kostyanev
FLFinola Leonard
Finola Leonard
JCJobiba Chinkhumba
Jobiba Chinkhumba
Background: Antimicrobial resistance (AMR) poses a significant threat to global health and economic development. In Malawi, the economic costs associated with the treatment of AMR infections remain largely unknown which may hinder resource allocation and policy prioritization. Method: The study used a cross-sectional design and was conducted between September 2023 and January 2025 at three different hospital settings. Data were collected from inpatients with laboratory-confirmed urinary tract infection (UTI) or blood stream infection (BSI). Additional follow-up data were collected from patients for four weeks post discharge. We analyzed patient level data first using descriptive statistics and employed an instrumental variable 2-stage least squares regression to estimate drivers of AMR treatments costs. Results: A total of 610 patients participated in the study. Of these, 45% had AMR-associated resistant infections. Overall, E. coli (43%) followed by P. aeruginosa (22%), K. pneumoniae (14%), and S. aureus (10%) were the most common pathogens. UTI was marginally more common (51%) compared to BSI (49%). BSI had a higher average cost than UTI for patients with both susceptible and resistant infections. On average, a patient spent MK283,815.10 (US$163.71) ranging from zero to MK13,500,000 (US$7786.90). Patients with resistant infections incurred, on average, MK161,785 (US$93.32) more than patients with susceptible infections, largely driven by prolonged hospitalization among other factors. Overall, the direct medical observed costs averaged MK37,165.29 (US$21.44) while direct non-medical observed costs averaged MK61,908.71 (US$35.71). Productivity losses for the patient and guardian(s) were a major observed cost averaging MK160,322.80 (US$92.49). The regression results further showed that having a bank account as a proxy of wealth, non-farm business, longer travel duration, BSI, and K. pneumoniae as the causative pathogens were significantly associated with increased cost burden among the patients. Conclusions: AMR-associated infections impose substantial economic burden on patients and households. Further strengthening of AMR surveillance and stewardship are needed as critical elements of Malawi’s National Action Plan. However, measures should also be taken to mitigate the economic consequences related to AMR, especially for patients who bear the brunt of these costs for lack of financial protection in Malawi’s health system.